D'Errico A, Grigioni W F, Fiorentino M, Baccarini P, Lamas E, De Mitri S, Gozzetti G, Mancini A M, Brechot C
Institute of Pathological Anatomy, University of Bologna, Italy.
Pathol Int. 1994 Feb;44(2):131-7. doi: 10.1111/j.1440-1827.1994.tb01697.x.
Recent results obtained using molecular biology techniques have suggested a possible role for insulin-like growth factor II (IGF-II) in the pathogenesis of hepatocellular carcinoma (HCC). To investigate this phenomenon, a monoclonal antibody was used against IGF-II to study 54 patients with HCC. The presence of HBsAg was also tested both in serum and liver tissue. A positive immunoreaction was found in 9/15 (60%) of the HCC arising in cirrhotic livers of patients who had serum markers for HBV (HBV + positive patients). These results provide further evidence that HBV might play a role in the expression of IGF-II. In HCC of patients without any markers of HBV infection (HBV- negative patients), IGF-II was detected in 10/39 (25.6%) of the tumors, and in some benign neoplastic lesions. It was found not only in neoplastic cells but also in some dysplastic nodules. The speculation arises that IGF-II expression may play a role in some steps of hepato-carcinogenesis.
近期运用分子生物学技术所获得的结果表明,胰岛素样生长因子II(IGF-II)在肝细胞癌(HCC)的发病机制中可能发挥作用。为了研究这一现象,使用了一种针对IGF-II的单克隆抗体来研究54例肝细胞癌患者。同时还检测了血清和肝组织中的HBsAg。在血清中有HBV标志物的患者(HBV阳性患者)的肝硬化肝脏中发生的15例HCC中,有9例(60%)出现了阳性免疫反应。这些结果进一步证明HBV可能在IGF-II的表达中发挥作用。在无任何HBV感染标志物的患者(HBV阴性患者)的HCC中,10/39(25.6%)的肿瘤以及一些良性肿瘤性病变中检测到了IGF-II。不仅在肿瘤细胞中发现了IGF-II,在一些发育异常的结节中也有发现。由此推测IGF-II的表达可能在肝癌发生的某些阶段发挥作用。